<?xml version="1.0" encoding="UTF-8"?>
<ref id="B10-vaccines-08-00174">
 <label>10.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lai</surname>
    <given-names>C.-Y.</given-names>
   </name>
   <name>
    <surname>Tsai</surname>
    <given-names>W.-Y.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>S.-R.</given-names>
   </name>
   <name>
    <surname>Kao</surname>
    <given-names>C.-L.</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>H.-P.</given-names>
   </name>
   <name>
    <surname>King</surname>
    <given-names>C.-C.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>H.-C.</given-names>
   </name>
   <name>
    <surname>Chang</surname>
    <given-names>G.-J.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>W.K.</given-names>
   </name>
  </person-group>
  <article-title>Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II</article-title>
  <source>J. Virol.</source>
  <year>2008</year>
  <volume>82</volume>
  <fpage>6631</fpage>
  <lpage>6643</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00316-08</pub-id>
  <pub-id pub-id-type="pmid">18448542</pub-id>
 </element-citation>
</ref>
